BR112019008762A2 - method for treating a flt3 mutated proliferative disorder - Google Patents
method for treating a flt3 mutated proliferative disorderInfo
- Publication number
- BR112019008762A2 BR112019008762A2 BR112019008762A BR112019008762A BR112019008762A2 BR 112019008762 A2 BR112019008762 A2 BR 112019008762A2 BR 112019008762 A BR112019008762 A BR 112019008762A BR 112019008762 A BR112019008762 A BR 112019008762A BR 112019008762 A2 BR112019008762 A2 BR 112019008762A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- crenolanib
- flt3
- treating
- genetic abnormalities
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Abstract
crenolanibe para tratar doenças proliferativas com mutação de flt3 associadas às mutações a presente invenção inclui os métodos para tratar uma doença proliferativa com mutação de flt3 compreendendo: medir a expressão de um flt3 com mutação e um ou mais anormalidades genéticas em uma amostra obtida de uma amostra de tumor obtida do paciente, em que a presença de uma ou mais anormalidades genéticas indica que o paciente tem um prognóstico deficiente; e administrar ao paciente uma quantidade terapeuticamente efetiva de crenolanibe ou seu sal farmaceuticamente aceitável, em que o crenolanibe aumenta uma chance de sobrevivência do paciente tanto com o flt3 com mutação e uma ou mais anormalidades genéticas, em que o crenolanibe, conforme abaixo mostrado, é administrado a uma pessoa sofrendo da referida doença.crenolanib for treating mutation-associated flt3 mutative proliferative diseases The present invention includes methods for treating a flt3 mutant proliferative disease comprising: measuring the expression of a mutated flt3 and one or more genetic abnormalities in a sample obtained from a sample a tumor obtained from the patient, where the presence of one or more genetic abnormalities indicates that the patient has a poor prognosis; and administering to the patient a therapeutically effective amount of crenolanib or its pharmaceutically acceptable salt, wherein crenolanib increases a patient's chance of survival with both mutated flt3 and one or more genetic abnormalities, wherein crenolanib, as shown below, is administered to a person suffering from said disease.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662416475P | 2016-11-02 | 2016-11-02 | |
US15/799,684 US11078541B2 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
PCT/US2017/059377 WO2018085292A1 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019008762A2 true BR112019008762A2 (en) | 2019-07-16 |
Family
ID=62020370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019008762A BR112019008762A2 (en) | 2016-11-02 | 2017-10-31 | method for treating a flt3 mutated proliferative disorder |
Country Status (19)
Country | Link |
---|---|
US (2) | US11078541B2 (en) |
EP (1) | EP3359155A4 (en) |
JP (2) | JP2019532011A (en) |
KR (2) | KR20200079351A (en) |
CN (1) | CN108778276A (en) |
AU (1) | AU2017353925A1 (en) |
BR (1) | BR112019008762A2 (en) |
CA (1) | CA3024012A1 (en) |
CL (1) | CL2019001208A1 (en) |
CO (1) | CO2019005466A2 (en) |
EA (1) | EA201991078A1 (en) |
HK (1) | HK1257195A1 (en) |
IL (1) | IL266303A (en) |
MX (1) | MX2019005008A (en) |
PE (1) | PE20191238A1 (en) |
PH (1) | PH12019500965A1 (en) |
SG (1) | SG11201903889TA (en) |
WO (1) | WO2018085292A1 (en) |
ZA (1) | ZA201903089B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3024012A1 (en) * | 2016-11-02 | 2018-05-11 | Arog Pharmaceuticals, Inc. | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
CN113164443A (en) * | 2018-09-26 | 2021-07-23 | 库拉肿瘤学公司 | Treatment of hematologic malignancies with multiple endocrine oncostatin inhibitors |
CN109678849A (en) * | 2019-01-16 | 2019-04-26 | 北京悦康科创医药科技股份有限公司 | A kind of preparation method of anticancer drug |
US11471451B2 (en) * | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
CN110531016B (en) * | 2019-09-05 | 2021-08-31 | 合肥诺明药物安全研究有限公司 | HYML-122 blood concentration quantitative analysis method |
WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
US11524006B2 (en) * | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
CN112921091B (en) * | 2021-03-16 | 2022-01-21 | 南京先声医学检验实验室有限公司 | Use of FLT3 gene mutation in predicting sensitivity of non-small cell lung cancer patient to immune checkpoint inhibitor therapy |
JP2023063189A (en) * | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | Crenolanib for treating flt3 mutated proliferative disorders relapsing after or refractory to prior treatment |
CN115141886B (en) * | 2022-06-28 | 2023-06-06 | 厦门艾德生物医药科技股份有限公司 | Probe primer set for detecting myelogenous leukemia gene mutation based on high-throughput sequencing and application thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
UA75055C2 (en) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon |
WO2002032861A2 (en) | 2000-10-17 | 2002-04-25 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
AR035885A1 (en) | 2001-05-14 | 2004-07-21 | Novartis Ag | DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION |
WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US7101884B2 (en) | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
ATE335490T1 (en) | 2001-10-30 | 2006-09-15 | Novartis Pharma Gmbh | STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTION |
MXPA04006271A (en) | 2001-12-27 | 2004-10-04 | Theravance Inc | Indolinone derivatives useful as protein kinase inhibitors. |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
JP4741948B2 (en) | 2002-08-14 | 2011-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | Protein kinase inhibitors and their use |
CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
PA8580301A1 (en) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS |
US20080207617A1 (en) | 2002-10-29 | 2008-08-28 | Kirin Beer Kabushiki Kaisha | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same |
BR0316229A (en) | 2002-11-13 | 2005-10-04 | Chiron Corp | Cancer Treatment Methods and Related Methods |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
DE60326646D1 (en) | 2002-12-18 | 2009-04-23 | Vertex Pharma | BENZINE OXAZOLE DERIVATIVES PROPER AS INHIBITORS OF PROTEIN KINASES |
KR100787649B1 (en) | 2003-06-24 | 2007-12-21 | 화이자 프로덕츠 인크. | Processes for the preparation of 1-[benzoimidazol-1-ylquinolin-8-yl]piperidin-4-ylamine derivatives |
SI2417267T1 (en) * | 2009-04-06 | 2017-02-28 | Vanda Pharmaceuticals Inc. | Method of treatment based on polymorphisms of the kcnq1 gene |
AU2013232379A1 (en) * | 2012-03-12 | 2014-09-25 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia |
TWI599356B (en) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | Method of inhibiting mutant c-kit |
BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanib for treatment of mutated flt3 proliferative disorders |
CA3024012A1 (en) * | 2016-11-02 | 2018-05-11 | Arog Pharmaceuticals, Inc. | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
-
2017
- 2017-10-31 CA CA3024012A patent/CA3024012A1/en active Pending
- 2017-10-31 BR BR112019008762A patent/BR112019008762A2/en not_active Application Discontinuation
- 2017-10-31 JP JP2018506309A patent/JP2019532011A/en active Pending
- 2017-10-31 PE PE2019000923A patent/PE20191238A1/en unknown
- 2017-10-31 KR KR1020207018302A patent/KR20200079351A/en not_active Application Discontinuation
- 2017-10-31 US US15/799,684 patent/US11078541B2/en active Active
- 2017-10-31 AU AU2017353925A patent/AU2017353925A1/en not_active Abandoned
- 2017-10-31 KR KR1020187016693A patent/KR20180074792A/en not_active Application Discontinuation
- 2017-10-31 MX MX2019005008A patent/MX2019005008A/en unknown
- 2017-10-31 SG SG11201903889TA patent/SG11201903889TA/en unknown
- 2017-10-31 CN CN201780016669.1A patent/CN108778276A/en active Pending
- 2017-10-31 EP EP17866388.6A patent/EP3359155A4/en active Pending
- 2017-10-31 EA EA201991078A patent/EA201991078A1/en unknown
- 2017-10-31 WO PCT/US2017/059377 patent/WO2018085292A1/en active Application Filing
-
2018
- 2018-12-18 HK HK18116172.6A patent/HK1257195A1/en unknown
-
2019
- 2019-04-29 IL IL266303A patent/IL266303A/en unknown
- 2019-04-30 PH PH12019500965A patent/PH12019500965A1/en unknown
- 2019-05-02 CL CL2019001208A patent/CL2019001208A1/en unknown
- 2019-05-17 ZA ZA2019/03089A patent/ZA201903089B/en unknown
- 2019-05-24 CO CONC2019/0005466A patent/CO2019005466A2/en unknown
-
2021
- 2021-06-23 US US17/355,468 patent/US20210324481A1/en active Pending
-
2022
- 2022-03-02 JP JP2022031616A patent/JP2022071099A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018085292A1 (en) | 2018-05-11 |
US20210324481A1 (en) | 2021-10-21 |
US20180117031A1 (en) | 2018-05-03 |
EA201991078A1 (en) | 2019-11-29 |
PE20191238A1 (en) | 2019-09-11 |
MX2019005008A (en) | 2019-09-10 |
PH12019500965A1 (en) | 2019-12-02 |
JP2022071099A (en) | 2022-05-13 |
KR20180074792A (en) | 2018-07-03 |
ZA201903089B (en) | 2019-12-18 |
CO2019005466A2 (en) | 2019-07-31 |
EP3359155A1 (en) | 2018-08-15 |
EP3359155A4 (en) | 2019-05-22 |
KR20200079351A (en) | 2020-07-02 |
JP2019532011A (en) | 2019-11-07 |
CA3024012A1 (en) | 2018-05-11 |
SG11201903889TA (en) | 2019-05-30 |
CN108778276A (en) | 2018-11-09 |
CL2019001208A1 (en) | 2019-07-26 |
AU2017353925A1 (en) | 2018-09-27 |
US11078541B2 (en) | 2021-08-03 |
IL266303A (en) | 2019-06-30 |
HK1257195A1 (en) | 2019-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019008762A2 (en) | method for treating a flt3 mutated proliferative disorder | |
Wang et al. | Anti-arthritic effect of berberine on adjuvant-induced rheumatoid arthritis in rats | |
BR112017023233A2 (en) | methods for cancer treatment | |
BR112015016282A2 (en) | crenolanib for treatment of mutated flt3 proliferative disorders | |
BR112015027682A2 (en) | USE OF SOBETIROME IN THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH DEMYELINATION OR INSUFFICIENT MYELINATION | |
BR112015029918A2 (en) | high-dose pridopidine to treat huntington's disease | |
Tao et al. | DHEA attenuates microglial activation via induction of JMJD3 in experimental subarachnoid haemorrhage | |
MX2017006938A (en) | Combination therapy for treatment of cancer. | |
Liu et al. | Citalopram alleviates chronic stress induced depression-like behaviors in rats by activating GSK3β signaling in dorsal hippocampus | |
BR112014029338A2 (en) | biomarkers for determining the effective response of hepatocellular carcinoma (hcc) treatment | |
BR112015022650A8 (en) | macrocyclic salt inducible kinase inhibitors. | |
BR112018012626A2 (en) | ccl20 as a predictor of clinical response to il23 antagonists | |
MX2021011269A (en) | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine. | |
EA201691656A2 (en) | THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS | |
NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
JP2016519107A5 (en) | ||
BR112015011099A2 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECTODERMAL DIPLASIA | |
PH12016500842A1 (en) | Use of cysteamine and derivatives thereof to treat mitochondrial diseases | |
Jimenez et al. | A phase 2 study to evaluate the effects of cabozantinib in patients with unresectable metastatic pheo-chromocytomas and paragangliomas | |
BR112019007028A2 (en) | Pharmaceutical Methods and Compositions for the Treatment of Kidney Cancer | |
BR112016024502A8 (en) | use of a dose of fine particles (pdf) of levodopa in the manufacture of a drug | |
Poverennova et al. | Diagnosis and treatment of asthenic syndrome in elderly people after acute respiratory viral infection | |
MX2020003682A (en) | Methods for treating diseases associated with ciliopathies. | |
Lyashenko et al. | Melatonin in correction of REM-sleep behavior disorders in Parkinson's disease | |
BR112016011811A2 (en) | USE OF AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR, THERAPEUTIC REGIME AND PACKAGE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |